Loading
A phase 3 trial of Zongertinib, Pembrolizumab, Atezolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Boehringer Ingelheim, now recruiting.
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations is a phase 3 interventional study registered as NCT07195695 by Boehringer Ingelheim, with 400 participants planned, started 2026-01-16 and due to reach its primary completion in 2032-02-26. Interventions recorded: Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zongertinib, Boehringer Ingelheim, HER2-mutant non-small-cell lung cancer, Pembrolizumab.
Shares Zongertinib, Boehringer Ingelheim, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares Atezolizumab, Nivolumab, Small-cell lung cancer, Pembrolizumab.
Shares Zongertinib, Boehringer Ingelheim, HER2-mutant non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Atezolizumab, Durvalumab, Nivolumab, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Nivolumab, Small-cell lung cancer, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/